Companies /Healthcare

Nurix Therapeutics Inc

NASDAQ: NRIX Biotechnology
$26.72
▼ $0.23 (−0.85%) today
Markets open · 3:26pm ET

Q2 2025 Earnings

Reported Jul 9, 2025, 4:02pm ET · SEC source
$-0.52
Beat +30.15%
EPS · est. $-0.74
$44.1M
Beat +151.56%
Revenue · est. $17.5M
−25.5%
Trailing market
NRIX vs S&P since report
2 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
0+20%+40%Jul 9Jul 10report 4:02pm ETearnings+0.3%−7.9%
0+20%+40%Jul 9Jul 10earnings+0.3%−7.9%
NRIX −7.9%S&P 500 +0.3%
0+20%+40%Jul 9Jul 10report 4:02pm ETearnings−0.1%−7.9%
0+20%+40%Jul 9Jul 10earnings−0.1%−7.9%
NRIX −7.9%NASDAQ −0.1%
−20%0+20%Jul 8Jul 17report 4:02pm ETearnings+0.7%−10.7%
−20%0+20%Jul 8Jul 17earnings+0.7%−10.7%
NRIX −10.7%S&P 500 +0.7%
−20%0+20%Jul 8Jul 17report 4:02pm ETearnings+1.1%−10.7%
−20%0+20%Jul 8Jul 17earnings+1.1%−10.7%
NRIX −10.7%NASDAQ +1.1%
−3.87%
Day of report
−1.82%
Next session
−4.58%
One week
−23.84%
30 days

S&P 500 over the same 30 days: +1.61%.

Did NRIX Beat Earnings? Q2 2025 Results

Nurix Therapeutics delivered a standout fiscal second quarter, with revenue of $44.06 million beating the $17.51 million consensus by 151.56% and a per-share loss of $0.52 coming in well ahead of the $0.74 estimate, representing a 30.15% positive surprise. The headline driver was collaboration activity, specifically $30.00 million in license revenue tied to two Sanofi license extensions, including the exercise of its option on the STAT6 program featuring degrader candidate NX-3911, alongside a $5.00 million clinical milestone from Gilead. Together, those payments helped push total revenue up 264.3% from $12.09 million in the year-ago quarter. Retail investor sentiment turned notably bullish following the report, with shares jumping on the results. Looking ahead, Nurix expects to initiate pivotal trials for lead asset bexobrutideg in relapsed/refractory CLL in the second half of calendar 2025, while a cash position of $485.80 million provides a firm financial foundation to advance its broader pipeline across oncology and autoimmune indications.

Key Takeaways
  • $30 million in license revenue from two Sanofi license extensions during the quarter
  • $5 million clinical milestone achieved under Gilead collaboration
  • Accelerated enrollment and pivotal trial preparation for bexobrutideg driving increased R&D spending

“During our second quarter, Nurix delivered important collaboration milestones, resulting in Sanofi's extension of its license for our STAT6 program and FDA clearance of the IND for IRAK4 degrader GS-6791/NX-0479 in collaboration with Gilead.”

Nurix Therapeutics CEO, on the earnings call

Forward Guidance & Outlook

Nurix remains on track to initiate pivotal trials for bexobrutideg in CLL in the second half of calendar 2025. The company is expanding bexobrutideg into autoimmune indications with a new Phase 1b cohort for CLL patients with autoimmune hemolytic anemia and exploring the filing of a non-malignant hematology IND for autoimmune cytopenias in 2025. Clinical updates for zelebrudomide (NX-2127) and NX-1607 are anticipated in the second half of 2025. Cash, cash equivalents and marketable securities of $485.8 million (excluding $19 million in post-quarter milestone payments) are expected to fund ongoing development activities.

NRIX YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$-30,000,000$0$30.0M$12.1M$44.1MRevenue$-48,105,525$-48,322,000Operating Income$-42,432,881$-43,464,000Net Income
$-30,000,000$0$30.0MRevenueOperating IncomeNet Income

NRIX Revenue by Segment

License Revenue$30.0M
Collaboration Revenue$14.1M

Figures from SEC filings and company reports. Not investment advice.